TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3065506

Group type: EXPERIMENTAL
Intervention: Nisoldipine, 10-20 mg daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31606437

Group type: EXPERIMENTAL
Intervention: EVLP plus UVC perfusate irradiation
Number of subjects: 22

Group type: COMPARATOR
Intervention: EVLP alone
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus velpatasvir treatment
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: HCV-positive donor lungs
Number of subjects: 22

Group type: COMPARATOR
Intervention: HCV-negative donor lungs
Number of subjects: 22
Study: 29596487

Group type: EXPERIMENTAL
Intervention: New odorant
Number of subjects: 17

Group type: COMPARATOR
Intervention: Hex-Hex Mix
Number of subjects: 17
Study: 27099485

Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg once a day for 3 days, then 250 mg once every 2 days for 3 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25633769

Group type: EXPERIMENTAL
Intervention: Cyberprogram 2.0
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 176
Study: 23415640

Group type: EXPERIMENTAL
Intervention: Orofacial manual therapy in addition to cervical manual therapy
Number of subjects: 43

Group type: COMPARATOR
Intervention: Cervical manual therapy (usual care)
Number of subjects: 43
Study: 21398433

Group type: EXPERIMENTAL
Intervention: NT-proBNP testing
Number of subjects: 68
Study: 18978633

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Mixed amphetamine salts
Number of subjects: 63
Study: 12233988

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study: 9585653

Group type: EXPERIMENTAL
Intervention: Routine care plus the intervention (n = 85)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Routine care (n = 77)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Subgroup without major depression (n not specified)
Number of subjects: 162
Study: 8589316

Group type: EXPERIMENTAL
Intervention: Dialysis Living Will
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Centre for Bioethics Living Will
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Medical Directive
Number of subjects: 95

Group type: COMPARATOR
Intervention: Generic ADs
Number of subjects: 95
Study: 2548759

Group type: EXPERIMENTAL
Intervention: Intracoronary injections of salbutamol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Intracoronary injections of salbutamol after practolol (beta 1-selective blockade)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Intracoronary injections of salbutamol after propranolol (beta 1- and beta 2-blockade)
Number of subjects: 24
Study: 326491

Group type: EXPERIMENTAL
Intervention: Mefenamic acid (500 mg t.d.s.)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Indomethacin (25 mg q.d.s.)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 31090563

Group type: EXPERIMENTAL
Intervention: Direct oral feeding after MIE
Number of subjects: 132

Group type: COMPARATOR
Intervention: Nil-by-mouth and tube feeding for 5 days postoperative (control)
Number of subjects: 132
Study: 28440007

Group type: EXPERIMENTAL
Intervention: Fluorescent hybrid zirconia abutment/crown (Test)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional one-piece zirconia abutment/crown (Control)
Number of subjects: 24
Study: 25723614

Group type: EXPERIMENTAL
Intervention: Standard-dose adalimumab (9.48 +/- 5.61 g/mL)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Low-dose adalimumab (3.51 +/- 2.21 g/mL)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Adalimumab dose escalation from every other week to weekly
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Higher serum adalimumab concentrations
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Baseline C-reactive protein and lower baseline albumin levels
Number of subjects: 192
Study: 23262179

Group type: EXPERIMENTAL
Intervention: Low-dose hydrocortisone (0.15mg/kg)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: High-dose hydrocortisone (0.45mg/kg)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 21768626

Group type: EXPERIMENTAL
Intervention: Total hip replacement
Number of subjects: 81

Group type: COMPARATOR
Intervention: Hemiarthroplasty
Number of subjects: 81
Study: 19543144

Group type: COMPARATOR
Intervention: Lactobacillus crispatus CTV-05 (LACTIN-V) administered by vaginal applicator at doses of 5 x 10, 1 x 10, and 2 x 10 cfu/dose for 5 consecutive days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo administered by vaginal applicator
Number of subjects: 12
Study: 16737494

Group type: EXPERIMENTAL
Intervention: Judgements on decision-making capacity based on patients' mental health status
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mental health status of patients
Number of subjects: 0
Study: 14744277

Group type: EXPERIMENTAL
Intervention: Carotid angioplasty and stenting (CAS)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 85
Study: 11254770

Group type: EXPERIMENTAL
Intervention: Paging system
Number of subjects: 143
Study: 9815725

Group type: EXPERIMENTAL
Intervention: neoadjuvant chemoendocrine therapy (four 3‐weekly cycles of chemotherapy with mitozantrone, methotrexate (+/‐ mitomycin C), and tamoxifen)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: neoadjuvant chemoendocrine therapy
Number of subjects: 90
Study: 7965154

Group type: EXPERIMENTAL
Intervention: Standardized uptake ratio (SUR)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Maximum activity ratio
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Average activity ratio
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Visual interpretation
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Overall accuracy
Number of subjects: 107
Study: 30238870

Group type: EXPERIMENTAL
Intervention: 10-ml/kg fluid bolus
Number of subjects: 75

Group type: COMPARATOR
Intervention: 20-ml/kg fluid bolus
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 75
Study: 27283780

Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training (PRT) intervention, 3 sessions per week for 12 weeks
Number of subjects: 22
Study: 24851943

Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia (TEA) with continuous administration of 0.25% bupivacaine
Number of subjects: 235

Group type: COMPARATOR
Intervention: General anaesthesia alone with intravenous analgesia (fentanyl: intubation 2 µg/kg; maintenance 0.1‐0.3 mg)
Number of subjects: 235
Study: 22116669

Group type: EXPERIMENTAL
Intervention: Landing Error Scoring System (LESS)
Number of subjects: 5047
Study: 20656955

Group type: EXPERIMENTAL
Intervention: Group A (with PVI)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Group B (without PVI)
Number of subjects: 40
Study: 19793848

Group type: EXPERIMENTAL
Intervention: Exercise in neutral temperature (25 degrees C)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Exercise in heat (36 degrees C)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (25 degrees C)
Number of subjects: 11
Study: 16802555

Group type: EXPERIMENTAL
Intervention: Standardized exercise training for 3 weeks (14 +/- 4 days after AMI)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group without exercise training
Number of subjects: 26
Study: 12593597

Group type: EXPERIMENTAL
Intervention: Nimesulide (100 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Naproxen (275 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 11783323

Group type: EXPERIMENTAL
Intervention: Salviae miltiorrhiza (SM) + cytosine diphosphate‐choline (CDP‐C)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: para‐aminomethyl benzoic acid (PAMBA) + CDP‐C
Number of subjects: 51

Group type: COMPARATOR
Intervention: CDP‐C
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Salviae miltiorrhiza (SM)
Number of subjects: 51
Study: 9337631

Group type: EXPERIMENTAL
Intervention: Interactive 2‐step theory of lexical retrieval
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Single‐word repetition task
Number of subjects: 21
Study: 8450107

Group type: EXPERIMENTAL
Intervention: Behavioral Marital Therapy (BMT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enhanced Behavioral Marital Therapy (EBMT)
Number of subjects: 0
Study: 3760275

Group type: EXPERIMENTAL
Intervention: Ketoconazole 2% cream
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 101
Study: 30646110

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Hypnosis (perceived)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control
Number of subjects: 148
Study: 26956126

Group type: COMPARATOR
Intervention: Heat-killed LP28
Number of subjects: 62
Study: 25008579

Group type: EXPERIMENTAL
Intervention: Soy-protein diet (30 g/d soy protein)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Soy-protein diet
Number of subjects: 15

Group type: COMPARATOR
Intervention: Mixed-protein diet
Number of subjects: 15
Study: 22811452

Group type: EXPERIMENTAL
Intervention: Educational session with relatives, including distribution of 5 posters about stroke signs and instructions to call 911.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (usual discharge plan).
Number of subjects: 60
Study: 20207926

Group type: EXPERIMENTAL
Intervention: Sitting position for PEF measurement
Number of subjects: 211

Group type: COMPARATOR
Intervention: Standing position for PEF measurement
Number of subjects: 211
Study: 18806203

Group type: EXPERIMENTAL
Intervention: MCS providing 15 mmHg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MCS providing 20 mmHg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MCS providing <10 mmHg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MCS providing >19 mmHg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MCS providing 4-9 mmHg (mean 7.3)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MCS providing 12-18 mmHg (mean 14.9)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MCS providing 18-22 mmHg (mean 19.5)
Number of subjects: 40
Study: 15709987

Group type: EXPERIMENTAL
Intervention: CDP571 (20 mg/kg at week 0 and 10 mg/kg at week 8)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 11792327

Group type: EXPERIMENTAL
Intervention: Direct stenting
Number of subjects: 411

Group type: COMPARATOR
Intervention: Conventional stenting with predilation
Number of subjects: 411
Study: 9934298

Group type: EXPERIMENTAL
Intervention: Practice Video Assessment (PVA)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Multiple-Station Examination (MSE)
Number of subjects: 90
Study: 8624225

Group type: EXPERIMENTAL
Intervention: Triclosan-copolymer mouthrinse
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 100
Study: 2184711

Group type: EXPERIMENTAL
Intervention: Mammacare group
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Traditional group
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 300
Study: 6157197

Group type: EXPERIMENTAL
Intervention: Debrisan (dextranomer)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (standard treatment)
Number of subjects: 100
Study: 30794101

Group type: EXPERIMENTAL
Intervention: S100B
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: GFAP
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: UCH-L1
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: SBDP150
Number of subjects: 566

Group type: COMPARATOR
Intervention: Baseline patient variables/characteristics
Number of subjects: 566
Study: 27029918

Group type: EXPERIMENTAL
Intervention: Iron-enriched yeast (2.5 mg 58Fe)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Ferrous sulfate (2.5 mg 57Fe)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Iron-enriched yeast (2.5 mg 58Fe) with bread and butter
Number of subjects: 32

Group type: COMPARATOR
Intervention: Ferrous sulfate (2.5 mg 57Fe) with bread and butter
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Iron-enriched yeast
Number of subjects: 32

Group type: COMPARATOR
Intervention: Ferrous sulfate
Number of subjects: 32
Study: 25836918

Group type: EXPERIMENTAL
Intervention: Hydroxytyrosol 5 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydroxytyrosol 25 mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydroxytyrosol (both doses)
Number of subjects: 0
Study: 24050512

Group type: EXPERIMENTAL
Intervention: Esomeprazole (20 mg b.i.d), tripotassium dicitrate bismuthate (300 mg q.i.d), metronidazole (500 mg t.i.d), and tetracycline (500 mg q.i.d) (EBMT)
Number of subjects: 648

Group type: COMPARATOR
Intervention: Moxifloxacin (400 mg q.d.), esomeprazole (20 mg b.i.d), and amoxicillin (1000 mg b.i.d.) (MEA)
Number of subjects: 648
Study: 21832979

Group type: EXPERIMENTAL
Intervention: Alfacalcidol
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Paricalcitol
Number of subjects: 80
Study: 19272686

Group type: EXPERIMENTAL
Intervention: C677T polymorphism (mutant TT genotype) in patients with ESRD
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: C677T polymorphism (all patients)
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: C677T polymorphism (patients with advanced CKD)
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Mutant T allele at nucleotide 677 (patients with ESRD)
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: A1298C polymorphism
Number of subjects: 677
Study: 17355722

Group type: EXPERIMENTAL
Intervention: Prototypical representatives under accountability
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Peripheral representatives under accountability
Number of subjects: 224
Study: 14697022

Group type: EXPERIMENTAL
Intervention: Ozone treatment
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control (air treatment)
Number of subjects: 89
Study: 11360072

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (2.5 ml of 0.5% bupivicaine)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Epidural anesthesia (15 ml of 0.5% bupivicaine)
Number of subjects: 65
Study: 9125675

Group type: EXPERIMENTAL
Intervention: Coadministration of acetazolamide with diuretic therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monotherapy with hydrochlorothiazide or furosemide
Number of subjects: 0
Study: 8150549

Group type: EXPERIMENTAL
Intervention: Cefpirome 0.5 g
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Cefpirome 1.0 g
Number of subjects: 5
Study: 2878632

Group type: EXPERIMENTAL
Intervention: Beta 2-agonist terbutaline (5 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Beta 1 + 2-agonist orciprenaline (10 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Beta 1-antagonist acebutolol (200 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Beta 1-antagonist metoprolol (50 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Beta 1 + 2-antagonist propranolol (5 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Beta 1 + 2-antagonist with ISA pindolol (5 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Beta 1-antagonists (acebutolol and metoprolol)
Number of subjects: 11
Study: 31993916

Group type: EXPERIMENTAL
Intervention: Unlabeled response options of the Minnesota Living with Heart Failure Questionnaire (MLHFQ)
Number of subjects: 1437

Group type: EXPERIMENTAL
Intervention: Standard approach to scoring and scores obtained by collapsing adjacent response categories
Number of subjects: 1437
Study: 31388755

Group type: EXPERIMENTAL
Intervention: Ovarian hyperstimulation‐IVF (COH‐IVF)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Modified natural cycle‐IVF (MNC‐IVF)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Naturally conceived to subfertile couples (Sub‐NC)
Number of subjects: 211
Study: 27035842

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion 0.5 μg/kg/h throughout the surgery after a loading dose of 1 μg/kg over 10 minutes, continued at 0.2 μg/kg/h for 24 hours postoperatively
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.9% saline (control group)
Number of subjects: 60
Study: 26154345

Group type: EXPERIMENTAL
Intervention: Resistance training + protein (whey 17 g + colostrum 3 g + leucine 2 g)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Resistance training + placebo
Number of subjects: 18
Study: 24162943

Group type: EXPERIMENTAL
Intervention: START intervention (manual based coping intervention)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Usual treatment alone
Number of subjects: 260
Study: 21029329

Group type: EXPERIMENTAL
Intervention: Static and dynamic knee extensions at 50% of 1RM
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Static and dynamic knee extensions at 75% of 1RM
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Static and dynamic knee extensions at 100% of 1RM
Number of subjects: 24
Study: 19577081

Group type: EXPERIMENTAL
Intervention: Controlled normoxic cardiopulmonary bypass (50-0 mm Hg)
Number of subjects: 67
Study: 17045959

Group type: EXPERIMENTAL
Intervention: Multiple extinction group (videotapes of the same spider in three different locations)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single extinction group (videotaped spider in one specific location)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (videotapes of the location without the spider)
Number of subjects: 0
Study: 15123970

Group type: EXPERIMENTAL
Intervention: Facilitated tucking
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard NICU care (nontucking)
Number of subjects: 40
Study: 11438317

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg daily per os)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 10097621

Group type: EXPERIMENTAL
Intervention: Dermatology-specific Quality of Life (DSQL) instrument
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8062311

Group type: EXPERIMENTAL
Intervention: Uniphyl (once-daily theophylline) in No Time Lapse (NTL) group
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Uniphyl (once-daily theophylline) in Time Lapse (TL) group
Number of subjects: 10
Study: 2661612

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 5, 10, 15, 20 mg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 31670530

Group type: EXPERIMENTAL
Intervention: Behavioral activation‐based intervention (7 sessions)
Number of subjects: 0
Study: 29753370

Group type: EXPERIMENTAL
Intervention: High-dose irbesartan combined with spironolactone (group D)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Low-dose irbesartan combined with spironolactone (group C)
Number of subjects: 244
Study: 28645301

Group type: EXPERIMENTAL
Intervention: Modified sternal precautions
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard sternal precautions
Number of subjects: 72
Study: 26176163

Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 733

Group type: COMPARATOR
Intervention: 23-valent pneumococcal polysaccharide vaccine (PPSV23)
Number of subjects: 733
Study: 23536690

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted tetravalent influenza vaccine
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Booster dose of tetravalent influenza vaccine
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Single dose of MF59-adjuvanted A/H5N1 vaccine
Number of subjects: 265
Study: 22235686

Group type: EXPERIMENTAL
Intervention: Qilin Pills, 6 g tid for 12 weeks
Number of subjects: 310

Group type: COMPARATOR
Intervention: Wuziyanzong Pills, 6 g bid for 12 weeks
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Qilin Pills
Number of subjects: 310

Group type: COMPARATOR
Intervention: Wuziyanzong Pills
Number of subjects: 310
Study: 19826646

Group type: EXPERIMENTAL
Intervention: APC + AI
Number of subjects: 172

Group type: COMPARATOR
Intervention: Hemoclips + AI
Number of subjects: 172
Study: 17181378

Group type: EXPERIMENTAL
Intervention: Subcutaneous PTH(1-84) 100 microg/day
Number of subjects: 2532

Group type: EXPERIMENTAL
Intervention: Subcutaneous PTH(1-84) 100 microg/day followed by alendronate 10 mg/day
Number of subjects: 2532

Group type: COMPARATOR
Intervention: PTH(1-84) in combination with alendronate
Number of subjects: 2532
Study: 15584815

Group type: EXPERIMENTAL
Intervention: Semantic priming with high cue validity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Semantic priming with low cue validity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stimulus intensity with high cue validity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stimulus intensity with low cue validity
Number of subjects: 0
Study: 11732460

Group type: EXPERIMENTAL
Intervention: Combined administration (DTP‐HBV‐Hib)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Separate administrations of DTP‐HBV and Hib vaccines
Number of subjects: 120
Study: 9395691

Group type: EXPERIMENTAL
Intervention: Active Enermed device (magnetically active), worn for 10-24 hours a day for 2 months.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo Enermed device (magnetically inactive), worn for 10-24 hours a day for 2 months.
Number of subjects: 30
Study: 7925202

Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 30
Study: 3134739

Group type: EXPERIMENTAL
Intervention: Magnyl (plain acetylsalicylic acid) 75 mg daily for 2 weeks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Globentyl (micro-encapsulated acetylsalicylic acid) 75 mg daily for 2 weeks
Number of subjects: 12
Study: 30739261

Group type: EXPERIMENTAL
Intervention: Dental injuries in females
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Crown fracture of maxillary teeth
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Root fracture in maxillary incisors and canines
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Avulsion, extrusion, and luxation
Number of subjects: 100
Study: 27148676

Group type: EXPERIMENTAL
Intervention: Modafinil (100 mg by mouth once daily, with a possible increase to 200 mg depending on response)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 40